Cases & Deals

Idenix defends nucleoside analogue patent in EPO opposition against five opponents

Clients Idenix Pharmaceuticals LLC

Jones Day represents Idenix Pharmaceuticals LLC (a subsidiary of Merck & Co., Inc.) in opposition proceedings before the EPO related to Idenix patent covering nucleoside analogs and prodrugs. Subject matter is nucleoside analogs and prodrugs for treating Flaviviridae infections, including HCV. The patent covers Gilead's marketing of Sovaldi® and Harvoni® for treatment of Hepatitis C.

Opposition Proceedings EP 1 523 489

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.